Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

SMC backs drug for male urinary symptoms in Scotland

  • Comment

The Scottish Medicines Consortium has approved solifenacin 6mg/tamsulosin 0.4mg (Vesomni) for use in NHS Scotland.

It has been accepted for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men not adequately responding to monotherapy.

Tamsulosin is an alpha-blocker, commonly prescribed to treat lower urinary tract symptoms associated with BPH due to its efficacy in relieving symptoms related to urinary voiding.

Solifenacin is an anti-muscarinic treatment used to treat urge incontinence and increased urinary frequency and urgency.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs